A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers

Journal of the National Cancer Institute

Volumn 95, Issue 11, 2003, Pages 779-790

  Decensi, Andrea ^a   Robertson, Chris ^a   Viale, Giuseppe ^a   Pigatto, Francesca ^a   Johansson, Harriet ^a   Kisanga, Elton R ^b   Veronesi, Paolo ^a   Torrisi, Rosalba ^a   Cazzaniga, Massimiliano ^a   Mora, Serena ^a   Sandri, Maria T ^a   Pelosi, Giuseppe ^a   Luini, Alberto ^a   Goldhirsch, Aron ^a   Lien, Ernst A ^c   Veronesi, Umberto ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF BERGEN   (Norway)

^c HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYTAMOXIFEN; ANTITHROMBIN III; BIOCHEMICAL MARKER; C PEPTIDE; C REACTIVE PROTEIN; CHOLESTEROL; COLLAGEN TYPE 1; DRUG METABOLITE; ESTROGEN RECEPTOR; FIBRINOGEN; KI 67 ANTIGEN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NORTAMOXIFEN; SEX HORMONE BINDING GLOBULIN; SOMATOMEDIN C; TAMOXIFEN; TRIACYLGLYCEROL; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; ESTROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TUMOR MARKER;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER RISK; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG TISSUE LEVEL; ENDOMETRIUM CANCER; ESTROGEN BLOOD LEVEL; FEMALE; FIBRINOGEN BLOOD LEVEL; FRACTURE; HIGH RISK PATIENT; HOT FLUSH; HUMAN; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS OF COVARIANCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; THROMBOEMBOLISM; TRIACYLGLYCEROL BLOOD LEVEL; VAGINA DISCHARGE; BLOOD; BREAST TUMOR; CHEMISTRY; DRUG ADMINISTRATION; GENE EXPRESSION REGULATION; IMMUNOHISTOCHEMISTRY; METHODOLOGY; MIDDLE AGED;

ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ESTROGEN RECEPTOR MODULATORS; ESTROGENS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MIDDLE AGED; RESEARCH DESIGN; TAMOXIFEN; TUMOR MARKERS, BIOLOGICAL;

EID: 0038467378     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/95.11.779     Document Type: Article

References (63)

1. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998;351: 1451-67.
2. Cuzick J, Powles T, Veronesi U, Forbes J, Edwards R, Ashley S, et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet 2003;361:296-300.
3. Graham JD, Bain DL, Richer JK, Jackson TA, Tung L, Horwitz KB. Thoughts on tamoxifen resistant breast cancer. Are coregulators the answer or just a red herring? J Steroid Biochem Mol Biol 2000;74:255-9.
4. Fisher B, Dignam J, Bryant J, Wolmark N. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from, the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst 2001;93:684-90.
5. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-88.
6. Wickerham DL, Fisher B, Wolmark N, Bryant J, Costantino J, Bernstein L, et al. Association of tamoxifen and uterine sarcoma. J Clin Oncol 2002; 20:2758-60.
7. First results from the International Breast Cancer Intervention Study (IBIS-1): a randomised prevention trial. Lancet 2002;360:817-24.
8. Shang Y, Brown M. Molecular determinants for the tissue specificity of SERMs. Science 2002;295:2465-8.
9. Shiota A, Igarashi T, Kurose T, Ohno M, Hando T. Reciprocal effects of tamoxifen on hormonal cytology in postmenopausal women. Acta Cytol 2002;46:499-506.
10. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002;359: 2131-9.
11. Jordan VC. Tamoxifen: too much of a good thing? J Clin Oncol 1999; 17: 2629-30.
12. Rutqvist LE, Johansson H, Signomklao T, Johansson U, Fornander T, Wilking N. Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. Stockholm Breast Cancer Study Group. J Natl Cancer Just 1995;87:645-51.
13. Coezy E, Borgna JL, Rochefort H. Tamoxifen and metabolites in MCF7 cells: correlation between binding to estrogen receptor and inhibition of cell growth. Cancer Res 1982;42:317-23.
14. Sutherland RL, Watts CK, Hall RE, Ruenitz PC. Mechanisms of growth inhibition by nonsteroidal antioestrogens in human breast cancer cells. J Steroid Biochem 1987;27:891-7.
15. Maltoni C, Minardi F, Belpoggi F, Pinto C, Lenzi A, Filippini F. Experimental results on the chemopreventive and side effects of tamoxifen using a human-equivalent animal model. In: Maltoni C, Soffritti M, Davis W, editors. The scientific bases of cancer chemoprevention. Amsterdam (The Netherlands): Elsevier Science; 1996. p. 197-207.
16. Decensi A, Bonanni B, Guerrieri-Gonzaga A, Gandini S, Robertson C, Johansson H, et al. Biologic activity of tamoxifen at low doses in healthy women. J Natl Cancer Inst 1998;90:1461-7.
17. Decensi A, Gandini S, Guerrieri-Gonzaga A, Johansson H, Manetti L, Bonanni B, et al. Effect of blood tamoxifen concentrations on surrogate biomarkers in a trial of dose reduction in healthy women. J Clin Oncol 1999;17:2633-8.
18. Makris A, Powles TJ, Allred DC, Ashley S, Ormerod MG, Titley JC, et al. Changes in hormone receptors and proliferation markers in tamoxifen treated breast cancer patients and the relationship with response. Breast Cancer Res Treat 1998;48:11-20.
19. Chang J, Powles TJ, Allred DC, Ashley SE, Makris A, Gregory RK, et al. Prediction of clinical outcome from primary tamoxifen by expression of biologic markers in breast cancer patients. Clin Cancer Res 2000;6: 616-21.
20. Kenny FS, Willsher PC, Gee JM, Nicholson R, Pinder SE, Ellis IO, et al. Change in expression of ER, bcl-2 and MIB1 on primary tamoxifen and relation to response in ER positive breast cancer. Breast Cancer Res Treat 2001;65:135-44.
21. Harper-Wynne CL, Sacks NP, Shenton K, MacNeill FA, Sauven P, Laidlaw IJ, et al. Comparison of the systemic and intratumoral effects of tamoxifen and the aromatase inhibitor vorozole in postmenopausal patients with primary breast cancer. J Clin Oncol 2002;20:1026-35.
22. Singletary SE, Atkinson EN, Hoque A, Sneige N, Sahin AA, Fritsche HA Jr, et al. Phase II clinical trial of N-(4-Hydroxyphenyl)retinamide and tamoxifen administration before definitive surgery for breast neoplasia. Clin Cancer Res 2002;8:2835-42.
23. Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 1998;351:1393-6.
24. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 2002;94:606-16.
25. Gould AL, Rossouw JE, Santanello NC, Heyse JF, Furberg CD. Cholesterol reduction yields clinical benefit. A new took at old data. Circulation 1995;91:2274-82.
26. LaRosa JC. Triglycerides and coronary risk in women and the elderly. Arch Intern Med 1997;157:961-8.
27. Koenig W. Fibrinogen and coronary risk. Curr Cardiol Rep 1999;1:112-8.
28. Ridker PM, Rifai N, Rose L, Baring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002;347:1557-65.
29. Kamphuisen PW, Eikenboom JC, Vos HL, Pablo R, Sturk A, Bertina RM, et al. Increased levels of factor VIII and fibrinogen in patients with venous thrombosis are not caused by acute phase reactions. Thromb Haemost 1999;81:680-3.
30. Chapurlat RD, Garnero P, Breart G, Meunier PJ, Delmas PD. Serum type I collagen breakdown product (serum CTX) predicts hip fracture risk in elderly women: the EPIDOS study. Bone 2000;27:283-6.
31. Sobin LH, Wittekind C, editors. TNM classification of malignant tumours. 5th ed. New York (NY): Wiley-Liss; 1997. p. 123-30.
32. Green S, Weiss GR. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs 1992;10: 239-53.
33. National Cancer Institute. Common toxicity criteria. 2nd ed. Bethesda (MD). 1999.
34. Buckley MM, Goa KL. Tamoxifen. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use. Drugs 1989;37: 451-90.
35. Adam HK, Patterson JS, Kemp JV. Studies on the metabolism and pharmacokinetics of tamoxifen in normal volunteers. Cancer Treat Rep 1980; 64:761-4.
36. Wagner JG, Northam JI, Alway CD, Carpenter OS. Blood levels of drug at the equilibrium state after multiple dosing. Nature 1965;207:1301-2.
37. Manzotti M, Dell'Orto P, Maisonneuve P, Fornaro M, Languino LR, Viale G. Down-regulation of beta(1C) integrin in breast carcinomas correlates with high proliferative fraction, high histological grade, and larger size. Am J Pathol 2000;156:169-74.
38. Jacobs TW, Gown AM, Yaziji H, Barnes MJ, Schnitt SJ. Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system. J Clin Oncol 1999;17:1983-7.
39. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
40. Lien EA, Ueland PM, Solheim E, Kvinnsland S. Determination of tamoxifen and four metabolites in serum by low-dispersion liquid chromatography. Clin Chem 1987;33:1608-14.
41. Lien EA, Solheim E, Ueland PM. Distribution of tamoxifen and its metabolites in rat and human tissues during steady-state treatment. Cancer Res 1991;51:4837-44.
42. Clarke RB, Laidlaw IJ, Jones LJ, Howell A, Anderson E. Effect of tamoxifen on Ki67 labelling index in human breast tumours and its relationship to oestrogen and progesterone receptor status. Br J Cancer 1993;67:606-11.
43. Dowsett M, Dixon JM, Horgan K, Salter J, Hills M, Harvey E. Antiproliferative effects of idoxifene in a placebo-controlled trial in primary human breast cancer. Clin Cancer Res 2000;6:2260-7.
44. Dowsett M, Bundred NJ, Decensi A, Sainsbury RC, Lu Y, Hills MJ, et al. Effect of raloxifene on breast cancer cell Ki67 and apoptosis: a double-blind, placebo-controlled, randomized clinical trial in postmenopausal patients. Cancer Epidemiol Biomarkers Prev 2001;10:961-6.
45. Robertson JF, Nicholson RI, Bundred NJ, Anderson E, Rayter Z, Dowsett M, et al. Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer. Cancer Res 2001;61:6739-46.
46. Benjamini Y, Hochberg Y. Controlling the false discovery rates-a practical and powerful approach to multiple testing. J Roy Stat Soc B 1995;57: 289-300.
47. Cohen I, Perel E, Tepper R, Flex D, Figer A, Shapira J, et al. Dose-dependent effect of tamoxifen therapy on endometrial pathologies in postmenopausal breast cancer patients. Breast Cancer Res Treat 1999;53: 255-62.
48. Bernardes JR Jr, Nonogaki S, Seixas MT, Rodrigues de Lima G, Baracat EC, Gebrim LH. Effect of a half dose of tamoxifen on proliferative activity in normal breast tissue. Int J Gynaecol Obstet 1999;67:33-8.
49. Reddel RR, Sutherland RL. Tamoxifen stimulation of human breast cancer cell proliferation in vitro: a possible model for tamoxifen tumour flare. Eur J Cancer Clin Oncol 1984;20:1419-24.
50. Greenberger LM, Annable T, Collins KI, Komm BS, Lyttle CR, Miller CP, et al. A new antiestrogen, 2-(4-hydroxy-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy) -benzyl]-1H-indol-5-ol hydrochloride (ERA-923), inhibits the growth of tamoxifen-sensitive and -resistant tumors and is devoid of uterotropic effects in mice and rats. Clin Cancer Res 2001;7: 3166-77.
51. Carthew P, Lee PN, Edwards RE, Heydon RT, Nolan BM, Martin EA. Cumulative exposure to tamoxifen: DNA adducts and liver cancer in the rat. Arch Toxicol 2001;75:375-80.
52. Guerrieri-Gonzaga A, Baglietto L, Johansson H, Bonanni B, Robertson C, Sandri MT, et al. Correlation between tamoxifen elimination and biomarker recovery in a primary prevention trial. Cancer Epidemiol Biomarkers Prev 2001;10:967-70.
53. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991;19:403-10.
54. Jordan VC, Fritz NF, Tormey DC. Long-term adjuvant therapy with tamoxifen: effects on sex hormone binding globulin and antithrombin III. Cancer Res 1987;47:4517-9.
55. Kailajarvi M, Ahokoski O, Virtanen A, Salminen E, Irjala K. Early effects of adjuvant tamoxifen therapy on serum hormones, proteins and lipids. Anticancer Res 2000;20:1323-7.
56. Barkhem T, Andersson-Ross C, Hoglund M, Nilsson S. Characterization of the "estrogenicity" of tamoxifen and raloxifene in HepG2 cells: regulation of gene expression from an ERE controlled reporter vector versus regulation of the endogenous SHBG and PS2 genes. J Steroid Biochem Mol Biol 1997;62:53-64.
57. Rutqvist LE, Mattsson A. Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. The Stockholm Breast Cancer Study Group. J Natl Cancer Inst 1993;85:1398-406.
58. McDonald CC, Alexander FE, Whyte BW, Forrest AP, Stewart HJ. Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial. The Scottish Cancer Trials Breast Group. BMJ 1995;311:977-80.
59. Reis SE, Costantino JP, Wickerham DL, Tan-Chiu E, Wang J, Kavanah M. Cardiovascular effects of tamoxifen in women with and without heart disease: breast cancer prevention trial. National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial Investigators. J Natl Cancer Inst 2001;93:16-21.
60. Johnston SR, Haynes BP, Smith IE, Jarman M, Sacks NP, Ebbs SR, et al. Acquired tamoxifen resistance in human breast cancer and reduced intratumoral drug concentration. Lancet 1993;342:1521-2.
61. O'Regan RM, Jordan VC. The evolution of tamoxifen therapy in breast cancer: selective oestrogen-receptor modulators and downregulators. Lancet Oncol 2002;3:207-14.
62. Winer EP, Hudis C, Burstein HJ, Chlebowski RT, Ingle JN, Edge SB, et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002. J Clin Oncol 2002;20: 3317-27.
63. Hershman D, Sundararajan V, Jacobson JS, Heitjan DF, Neugut AI, Grann VR. Outcomes of tamoxifen chemoprevention for breast cancer in very high-risk women: a cost-effectiveness analysis. J Clin Oncol 2002;20:9-16.